Newton, HS; Gawali, VS; Chimote, AA; Lehn, MA; Palackdharry, SM; Hinrichs, BH; Jandarov, R; Hildeman, D; Janssen, EM; Wise-Draper, TM; et al.
PD1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer.
Journal for ImmunoTherapy of Cancer.
2020;
8:e000844.
Almanan, M; Raynor, J; Ogunsulire, I; Malyshkina, A; Mukherjee, S; Hummel, SA; Ingram, JT; Saini, A; Xie, MM; Alenghat, T; et al.
IL-10-producing Tfh cells accumulate with age and link inflammation with age-related immune suppression.
Science Advances.
2020;
6:eabb0806.
Woodle, ES; Tremblay, S; Rossi, A; Rojas, CC; Alloway, R; Roskin, K; Allman, D; Hildeman, D.
Plasma cell targeting to prevent antibody-mediated rejection.
American Journal of Transplantation.
2020;
20 Suppl 4:33-41.
Newton, H; Gawali, VS; Chimote, AA; Lehn, M; Palackdharry, S; Hildeman, D; Janssen, E; Wise-Draper, T; Conforti, L.
Pembrolizumab treatment increases K+ channel function and calcium fluxes in cytotoxic T cells of head and neck cancer patients.
Journal of immunology (Baltimore, Md. : 1950).
2020;
204:165.41.
Castro-Rojas, CM; Godarova, A; Shi, T; Hummel, SA; Shields, A; Tremblay, S; Alloway, RR; Jordan, MB; Woodle, ES; Hildeman, DA.
mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Transplantation.
2020;
104:1058-1069.
Li, K; Ladle, BH; Kurtulus, S; Sholl, A; Shanmuganad, S; Hildeman, DA.
T-cell receptor signal strength and epigenetic control of Bim predict memory CD8+ T-cell fate.
Cell Death and Differentiation.
2020;
27:1214-1224.
Raynor, J; Lin, A; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA.
The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection.
Frontiers in Immunology.
2020;
11:197.
Tremblay, S; Driscoll, JJ; Rike-Shields, A; Hildeman, DA; Alloway, RR; Girnita, AL; Brailey, PA; Woodle, ES.
A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
American Journal of Transplantation.
2020;
20:411-421.